Cellectis S.A. (NASDAQ:CLLS) Sees Large Growth in Short Interest

Cellectis S.A. (NASDAQ:CLLS) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 221,300 shares, an increase of 34.0% from the January 15th total of 165,200 shares. Based on an average trading volume of 139,900 shares, the short-interest ratio is presently 1.6 days.

Analysts Set New Price Targets

CLLS has been the topic of a number of research reports. StockNews.com initiated coverage on Cellectis in a report on Friday, January 24th. They issued a “buy” rating on the stock. Barclays lowered their target price on Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Trading Up 1.3 %

Shares of NASDAQ:CLLS traded up $0.02 during trading on Friday, reaching $1.55. 77,558 shares of the company traded hands, compared to its average volume of 167,729. The firm has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $1.93. Cellectis has a 1-year low of $1.41 and a 1-year high of $3.38. The company has a current ratio of 1.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.48.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Cellectis stock. Wells Fargo & Company MN increased its stake in shares of Cellectis S.A. (NASDAQ:CLLS) by 103.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,590 shares of the biotechnology company’s stock after purchasing an additional 12,500 shares during the quarter. Wells Fargo & Company MN’s holdings in Cellectis were worth $44,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.